Endothelium-dependent coronary vasomotor response and neointimal coverage of zotarolimus-eluting stents 3 months after implantation

Heart

Volumn 97, Issue 12, 2011, Pages 977-982

  Fujii, Kenichi ^a   Kawasaki, Daizo ^a   Oka, Katsumi ^a   Akahori, Hirokuni ^a   Fukunaga, Masashi ^a   Sawada, Hisashi ^a   Masutani, Motomaru ^a   Lee Kawabata, Masaaki ^a   Tsujino, Takeshi ^a   Ohyanagi, Mitsumasa ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ZOTAROLIMUS;

AGED; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY; CROSS-SECTIONAL STUDY; DRUG ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; MALE; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; VASOCONSTRICTION;

ACETYLCHOLINE; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; CORONARY VESSELS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEOINTIMA; PROSPECTIVE STUDIES; SIROLIMUS; TOMOGRAPHY, OPTICAL COHERENCE; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; VASOMOTOR SYSTEM; WOUND HEALING;

EID: 79956308487     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.204594     Document Type: Article

References (27)

1. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008. (Pubitemid 46376800)
2. Abbott JD, Voss MR, Nakamura M, et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007;50:2029-36. (Pubitemid 350087575)
3. Babapulle MN, Joseph L, Bélisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-91. (Pubitemid 39094175)
4. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-2. (Pubitemid 38544480)
5. Takano M, Yamamoto M, Inami S, et al. Long-term follow-up evaluation after sirolimus-eluting stent implantation by optical coherence tomography: do uncovered struts persist? J Am Coll Cardiol 2008;51:968-9. (Pubitemid 351282461)
6. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41. (Pubitemid 46717966)
7. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000;83:338-45. (Pubitemid 30313341)
8. Miyazawa A, Ako J, Hongo Y, et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008;155:108-13. (Pubitemid 350234763)
9. Kim JS, Jang IK, Kim JS, et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart 2009;95:1907-12.
10. Kim JS, Jang IK, Fan C, et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv 2009;2:1240-7.
11. Kim JW, Seo HS, Park JH, et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction. J Am Coll Cardiol 2009;53:1653-9.
12. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001;37:1478-92.
13. Chen BX, Ma FY, Luo W, et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart 2008;94:566-70. (Pubitemid 351580126)
14. Tanigawa J, Barlis P, Di Mario C. Intravascular optical coherence tomography: optimisation of image acquisition and quantitative assessment of stent strut apposition. EuroIntervention 2007;3:128-36.
15. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8. (Pubitemid 40982311)
16. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. (Pubitemid 40617065)
17. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-6. (Pubitemid 37243657)
18. Grewe PH, Deneke T, Machraoui A, et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-63. (Pubitemid 30061274)
19. Shin DI, Kim PJ, Seung KB, et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 2007;48:553-67.
20. Kasprzak JD, Kłosińska M, Drozdz J. Clinical aspects of assessment of endothelial function. Pharmacol Rep 2006;58:33-40.
21. Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006;27:166-70. (Pubitemid 43069032)
22. Kim JW, Suh SY, Choi CU, et al. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent. JACC Cardiovasc Interv 2008;1:65-71. (Pubitemid 351445416)
23. Mohacsi PJ, Tüller D, Hulliger B, et al. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997;16:484-92. (Pubitemid 27287777)
24. Axel DI, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45. (Pubitemid 27329445)
25. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7. (Pubitemid 44881222)
26. Nakazawa G, Finn AV, John MC, et al. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007;100:36M-44M.
27. Garcia-Touchard A, Burke SE, Toner JL, et al. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 2006;27:988-93.